Cited by 1,275Liver Disease Diagnosis and TreatmentUltrasound Imaging and ElastographyUltrasound in Clinical Applications

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Open access

Karlas, Thomas, Petroff, David, Sasso, Magali, Fan, Jian-Gao, Mi, Yu-Qiang, de Lédinghen, Victor, Kumar, Manoj, Lupsor-Platon, Monica, Han, Kwang-Hyub, Cardoso, Ana C., Ferraioli, Giovanna, Chan, Wah-Kheong, Wong, Vincent Wai-Sun, Myers, Robert P., Chayama, Kazuaki, Friedrich-Rust, Mireen, Beaugrand, Michel, Shen, Feng, Hiriart, Jean-Baptiste, Sarin, Shiv K., Badea, Radu, Jung, Kyu Sik, Marcellin, Patrick, Filice, Carlo, Mahadeva, Sanjiv, Wong, Grace Lai-Hung, Crotty, Pam, Masaki, Keiichi, Bojunga, Joerg, Bedossa, Pierre, Keim, Volker, Wiegand, Johannes·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2016.12.022

Open this paper in CoChat — free account

Abstract

Background & aims The prevalence of fatty liver underscores the need for non-invasive characterization of steatosis, such as the ultrasound based controlled attenuation parameter (CAP). Despite good diagnostic accuracy, clinical use of CAP is limited due to uncertainty regarding optimal cut-offs and the influence of covariates. We therefore conducted an individual patient data meta-analysis.Methods A review of the literature identified studies containing histology verified CAP data (M probe, vibration controlled transient elastography with FibroScan®) for grading of steatosis (S0-S3). Receiver operating characteristic analysis after correcting for center effects was used as well as mixed models to test the impact of covariates on CAP. The primary outcome was establishing CAP cut-offs for distinguishing steatosis grades.Results Data from 19/21 eligible papers were provided, comprising 3830/3968 (97%) of patients. Considering data overlap and exclusion criteria, 2735 patients were included in the final analysis (37% hepatitis B, 36% hepatitis C, 20% NAFLD/NASH, 7% other). Steatosis distribution was 51%/27%/16%/6% for S0/S1/S2/S3. CAP values in dB/m (95% CI) were influenced by several covariates with an estimated shift of 10 (4.5-17) for NAFLD/NASH patients, 10 (3.5-16) for diabetics and 4.4 (3.8-5.0) per BMI unit. Areas under the curves were 0.823 (0.809-0.837) and 0.865 (0.850-0.880) respectively. Optimal cut-offs were 248 (237-261) and 268 (257-284) for those above S0 and S1 respectively.Conclusions CAP provides a standardized non-invasive measure of hepatic steatosis. Prevalence, etiology, diabetes, and BMI deserve consideration when interpreting CAP. Longitudinal data are needed to demonstrate how CAP relates to clinical outcomes.Lay summary There is an increase in fatty liver for patients with chronic liver disease, linked to the epidemic of the obesity. Invasive liver biopsies are considered the best means of diagnosing fatty liver. The ultrasound based controlled attenuation parameter (CAP) can be used instead, but factors such as the underlying disease, BMI and diabetes must be taken into account. Registration: Prospero CRD42015027238.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2016.12.022

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statisctics and computing/Statistics and computing · doi:10.1007/978-0-387-21706-2 · Cited by 25,941
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Fitting Linear Mixed-Effects Models Using lme4Preprint
Bates, D. M., Maechler, M., Bolker, B. M., & Walker, S. (2014) · arXiv (Cornell University) · doi:10.3929/ethz-b-000105397 · Cited by 9,435
Histological grading and staging of chronic hepatitis.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., Groote, J. D., Gudat, F., Denk, H., Desmet, V., Korb, G., Macsween, R. N., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,290
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
Bédossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,189
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2015) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,002

Flagged first, then by citations

Show all 65 references

1 of the 65 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 1,000

Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes
Mak, L., Hui, R. W., Lee, C., Mao, X., Cheung, K. S., Wong, D. K.-H., Lui, D. T. W., Fung, J., Yuen, M., & Seto, W. (2022) · Hepatology · doi:10.1002/hep.32716 · Cited by 64
Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRI-PDFF as the gold standard
Shin, J., Kim, M., Shin, H. J., Yoon, H., Kim, S., Koh, H., & Lee, M. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1485-8 · Cited by 64
Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques
Park, J., Lee, J. M., Lee, G., Jeon, S. K., & Joo, I. (2022) · Korean Journal of Radiology · doi:10.3348/kjr.2021.0112 · Cited by 63
Novel ultrasound-based methods to assess liver disease: The game has just begun
Berzigotti, A., Ferraioli, G., Bota, S. I., Gilja, O. H., & Dietrich, C. F. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.11.019 · Cited by 62
Self-citation
Ultrasonic fat fraction quantification using in vivo adaptive sound speed estimation
Imbault, M., Burgio, M. D., Faccinetto, A., Ronot, M., Bendjador, H., Deffieux, T., Triquet, E. O., Rautou, P., Castéra, L., Gennisson, J., et al. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aae661 · Cited by 62
Fibrosis evolution in chronic hepatitis B e antigen‐negative patients across a 10‐year interval
Mak, L., Seto, W., Hui, R. W., Fung, J., Wong, D. K.-H., Lai, C., & Yuen, M. (2019) · Journal of Viral Hepatitis · doi:10.1111/jvh.13095 · Cited by 62
Sex Differences in Association Between Gut Microbiome and Essential Hypertension Based on Ambulatory Blood Pressure Monitoring
Virwani, P. D., Qian, G., Hsu, M. S. S., Pijarnvanit, T. K. K. T. S., Cheung, C. N.-M., Chow, Y. H., Lok Kan, T. A. N. G., Tse, Y.-H., Xian, J.-W., Shirley Sau-Wing, L. A. M., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.20752 · Cited by 66
The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities
Maevskaya, M. V., Kotovskaya, Y. V., Ivashkin, V. T., Ткачева, О. Н., Troshina, E. A., Shestakova, M. V., Breder, V. V., Geyvandova, N. I., Doshchitsin, V. L., Dudinskaya, Е. N., et al. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.02.201363 · Cited by 66
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.003 · Cited by 70
Clinical relevance of liver histopathology and different histological classifications of NASH in adults
Nascimbeni, F., Ballestri, S., Machado, M., Mantovani, A., Cortez-Pinto, H., Targher, G., & Lonardo, A. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1415756 · Cited by 56
Quantification of Liver Fibrosis, Steatosis, and Viscosity Using Multiparametric Ultrasound in Patients with Non-Alcoholic Liver Disease: A “Real-Life” Cohort Study
Popa, A., Bende, F., Șirli, R., Popescu, A., Bâldea, V., Lupușoru, R., Cotrău, R., Fofiu, R., Foncea, C. G., & Sporea, I. (2021) · Diagnostics · doi:10.3390/diagnostics11050783 · Cited by 59
Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection
Mak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Li, B., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2021) · Hepatology International · doi:10.1007/s12072-021-10218-2 · Cited by 58
Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
Fouad, Y. M., Alboraie, M. A. A., & Shiha, G. E.-S. (2024) · Hepatology International · doi:10.1007/s12072-024-10704-3 · Cited by 58
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
Magaz, M., Giudicelli, H., Abraldeṣ, J. G., Nicoară-Farcău, O., Turón, F., Rajoriya, N., Goel, A., Raymenants, K., Hillaire, S., Téllez, L., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.035 · Cited by 58
Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease
Zhang, X., Goh, G. B., Chan, W., Wong, G. L., Fan, J., Seto, W., Huang, Y., Lin, H., Lee, I., Lee, H. W., et al. (2020) · Liver International · doi:10.1111/liv.14638 · Cited by 58
Self-citation
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
Pelusi, S., & Valenti, L. V. C. (2018) · Liver International · doi:10.1111/liv.13972 · Cited by 59
Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients
Siddiqui, M. S., Idowu, M. O., Stromberg, K. A., Sima, A. P., Lee, E., Patel, S. S., Ghaus, S., Driscoll, C. J., Sterling, R. K., John, B. V., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.03.067 · Cited by 56
Non-invasive tests of non-alcoholic fatty liver disease
Li, G., Zhang, X., Lin, H., Liang, L. Y., Wong, G. L., & Wong, V. W. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002027 · Cited by 56
Self-citation
Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis
Shen, F., Mi, Y., Xu, L., Liu, Y., Wang, X., Pan, Q., Zhang, R., Hu, X., Xu, L., & Fan, J. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15298 · Cited by 56
Self-citation
Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients
Enooku, K., Tsutsumi, T., Kondo, M., Fujiwara, N., Sasako, T., Shibahara, J., Kado, A., Okushin, K., Fujinaga, H., Nakagomi, R., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01633-2 · Cited by 59
Novel reliability criteria for controlled attenuation parameter assessments for non‐invasive evaluation of hepatic steatosis
Semmler, G., Wöran, K., Scheiner, B., Unger, L. W., Paternostro, R., Stift, J., Schwabl, P., Bucsics, T., Bauer, D. J. M., Simbrunner, B., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640619900820 · Cited by 56
A meta‐analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease
Gu, Q., Li, C., Lai, J., Zhang, Z., Pan, J., Zhao, F., Yu, C., Li, Y., Chen, C., Chen, W., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13446 · Cited by 58
Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk—A Single-Center Cross-Sectional Study
Semmler, G., Wernly, S., Bachmayer, S., Wernly, B., Schwenoha, L., Huber-Schönauer, U., Stickel, F., Niederseer, D., Aigner, E. S., & Datz, C. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000326 · Cited by 54
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12280 · Cited by 62
Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal
Božić, D., Podrug, K., Mikolašević, I., & Grgurević, I. (2022) · Diagnostics · doi:10.3390/diagnostics12102287 · Cited by 54
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 56
Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography
Rout, G., Nayak, B., Patel, A. H., Gunjan, D., Singh, V., Kedia, S., & Shalimar, S. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.06.009 · Cited by 54
Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations
Arrese, M. A., Francisco Barrera, M., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 56
A critical appraisal of the use of ultrasound in hepatic steatosis
Ballestri, S., Nascimbeni, F., Lugari, S., Lonardo, A., & Francica, G. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1621164 · Cited by 53
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates
Garteiser, P., Castéra, L., Coupaye, M., Doblas, S., Calabrese, D., Burgio, M. D., Ledoux, S., Bédossa, P., Esposito‐Farèse, M., Msika, S., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100381 · Cited by 52
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement
Karlas, T., Petroff, D., Sasso, M., Fan, J., Mi, Y., de Lédinghen, V., Kumar, M. S., Lupșor‐Platon, M., Han, K., Cardoso, A. C., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14529 · Cited by 52
Self-citation
Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
Dorairaj, V., Sulaiman, S. A., Abu, N., & Murad, N. A. A. (2021) · Biomedicines · doi:10.3390/biomedicines10010015 · Cited by 52
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
Kawagishi, N., Suda, G., Nakamura, A., Kimura, M., Maehara, O., Suzuki, K., Nakamura, A., Ohara, M., Izumi, T., Umemura, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209615 · Cited by 50
Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus
Cervo, A., Milić, J., Mazzola, G. C., Schepis, F., Petta, S., Krahn, T., Lebouché, B., Deschênes, M., Cascio, A., Guaraldi, G., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa430 · Cited by 49
Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes
Lee, C., Seto, W., Lui, D. T. W., Fong, C. H.-Y., Wan, H. Y., Cheung, C. Y. Y., Chow, W.-S., Woo, Y. C., Yuen, M., Xu, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0131 · Cited by 49
Can the same controlled attenuation parameter cut‐offs be used for M and XL probes for diagnosing hepatic steatosis?
Chan, W., Mustapha, N. R. N., Mahadeva, S., Wong, V. W., Cheng, J. Y., & Wong, G. L. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14150 · Cited by 49
Self-citation
Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience
Sporea, I., Mare, R. G., Popescu, A., Nistorescu, S., Bâldea, V., Șirli, R., Braha, A., Sima, A. C., Timar, R. Z., & Lupușoru, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041032 · Cited by 49
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
Cardoso, C. R. L., Villela‐Nogueira, C. A., Leite, N. C., & Salles, G. F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01388-2 · Cited by 52
The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
Alkhouri, N., Almomani, A., Le, P., Payne, J. Y., Asaad, I., Sakkal, C., Vos, M. B., Noureddin, M., & Kumar, P. N. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02430-7 · Cited by 48
High prevalence of non‐alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors
Duran-Vian, C., Arias, M., Hernández, J. L., Fernández, V., González, M., Iruzubieta, P., Rasines, L., González‐Vela, C., Vaque, J. P., Blanco, R., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15764 · Cited by 48
Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies
Jang, J. K., Choi, S. H., Lee, J. S., Kim, S. Y., Lee, S. S., & Kim, K. W. (2021) · ULTRASONOGRAPHY · doi:10.14366/usg.21076 · Cited by 48
Letter regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”
Mak, L., Yuen, M., & Seto, W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.008 · Cited by 48
Time-restricted fasting improves liver steatosis in non-alcoholic fatty liver disease—a single blinded crossover trial
Feehan, J., Mack, A., Tuck, C., Tchongue, J., Holt, D. Q., Sievert, W., Moore, G. T., de Courten, B., & Hodge, A. (2023) · Nutrients · doi:10.3390/nu15234870 · Cited by 47
The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Fouad, Y. M., Esmat, G., Elwakil, R., Zakaria, S., Yosry, A., Waked, I. A., El-Razky, M., Doss, W. H., El‐Serafy, M., Mostafa, E., et al. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_357_21 · Cited by 49
Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?
Gudan, A., Kozłowska‐Petriczko, K., Wunsch, E., Bodnarczuk, T., & Stachowska, E. (2023) · Nutrients · doi:10.3390/nu15061323 · Cited by 55
Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease
Zou, H., Ma, X., Zhang, F., & Xie, Y. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01902-3 · Cited by 49
AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension
Sterling, R. K., Asrani, S. K., Levine, D., Duarte‐Rojo, A., Patel, K., Fiel, M. I., Leung, D. H., Taouli, B. A., Alsawas, M., Murad, M. H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000844 · Cited by 47
Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter
Shimizu, K., Soroida, Y., Sato, M., Hikita, H., Kobayashi, T., Endo, M., Sato, M., Gotoh, H., Iwai, T., Tateishi, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26293-9 · Cited by 47
Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness
Chow, J. C., Wong, G. L., Chan, A. W., Shu, S. S., Chan, C. K., Leung, J. K., Choi, P. C., Chim, A. M., Chan, H. L., & Wong, V. W. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14311 · Cited by 46
Self-citation
Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
Tomah, S., Hamdy, O., Abuelmagd, M. M., HASSAN, A. H., Alkhouri, N., Al-Badri, M. R., Gardner, H. M., Eldib, A. H., & Eid, E. A. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000780 · Cited by 46
Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection
Benmassaoud, A., Ghali, P., Cox, J., Wong, P. Y. N., Szabo, J., Deschênes, M., Osikowicz, M., Lebouché, B., Klein, M. B., & Sebastiani, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191985 · Cited by 46
Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus
Chen, K., Sng, W. K., Quah, J. H. M., Liu, J., Chong, B. Y., Lee, H. K., Wang, X. F., Tan, N. C., Chang, J. P.-E., Tan, H. C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236977 · Cited by 46
Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization
Fetzer, D. T., Rosado-Méndez, I. M., Wang, M. H., Robbin, M. L., Ozturk, A., Wear, K. A., Ormachea, J., Stiles, T. A., Fowlkes, J. B., Hall, T. J., et al. (2022) · Radiology · doi:10.1148/radiol.212808 · Cited by 45
Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease
Karlas, T., Weise, L., Kuhn, S., Krenzien, F., Mehdorn, M., Petroff, D., Linder, N., Schaudinn, A., Busse, H., Keim, V., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1208-6 · Cited by 45
Self-citation
Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
Scheiner, B., Steininger, L., Semmler, G., Unger, L. W., Schwabl, P., Bucsics, T., Paternostro, R., Ferlitsch, A., Trauner, M. A., Reiberger, T., et al. (2018) · Liver International · doi:10.1111/liv.13943 · Cited by 45
Recent advances in understanding and managing non-alcoholic fatty liver disease
Albhaisi, S. A. M., & Sanyal, A. J. (2018) · F1000Research · doi:10.12688/f1000research.14421.1 · Cited by 44
Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease
Altamirano, J., Qi, Q., Choudhry, S., Abdallah, M., Singal, A. K., Humar, A., Bataller, R. A., Borhani, A. A., & Duarte‐Rojo, A. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.11.14 · Cited by 45
Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan
Shida, T., Oshida, N., Suzuki, H., Okada, K., Watahiki, T., Oh, S., Kim, T., Isobe, T., Okamoto, Y., Ariizumi, S., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13543 · Cited by 45
Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease.
Miele, L., Zocco, M., Pizzolante, F., Matthaeis, N. D., Ainora, M., Liguori, A., Gasbarrini, A., Grieco, A., & Rapaccini, G. (2020) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2020.154355 · Cited by 42
Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
Bischoff, S. C., Ockenga, J., Eshraghian, A., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Kani, H. T., Khannoussi, W., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.03.021 · Cited by 47
The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter
Lee, H. W., Kim, K. J., Jung, K. S., Chon, Y. E., Huh, J. H., Park, K. H., Chung, J. B., Kim, C. O., Han, K., & Park, J. Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187066 · Cited by 44
Self-citation
Body mass index–based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease
Shalimar, S., Kumar, R. K., Rout, G., Kumar, R., Yadav, R., Das, P., Aggarwal, S., Gunjan, D., Saraya, A., & Nayak, B. (2020) · Indian Journal of Gastroenterology · doi:10.1007/s12664-019-00991-2 · Cited by 44
Changing clinical management of NAFLD in Asia
Nakatsuka, T., Tateishi, R., & Koike, K. (2021) · Liver International · doi:10.1111/liv.15046 · Cited by 44
Screening strategy for non-alcoholic fatty liver disease
Zhang, S., Mak, L., Yuen, M., & Seto, W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0336 · Cited by 44
Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity
Eilenberg, M., Munda, P., Stift, J., Langer, F. B., Prager, G., Trauner, M., & Staufer, K. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-787 · Cited by 42
Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication – comparison of the new direct-acting antiviral agents with the old regimens
Carvalho, J. R., Velosa, J., & Serejo, F. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1473486 · Cited by 43
Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease
Gao, B., Lang, S., Duan, Y., Wang, Y., Shawcross, D. L., Louvet, A., Mathurin, P., Ho, S. B., Stärkel, P., & Schnabl, B. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05638-y · Cited by 43
NAFLD in type 1 diabetes: overrated or underappreciated?
Mertens, J., Gaal, L. F. V., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211055557 · Cited by 44
Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications
Zeng, K., Bao, W.-Y.-G., Wang, Y., Liao, M., Yang, J., Huang, J.-Y., & Lü, Q. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i17.2534 · Cited by 41
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
Wai, J. W., Fu, C., & Wong, V. W. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01686-8 · Cited by 41
Self-citation
Normal liver stiffness and influencing factors in healthy children: An individual participant data meta‐analysis
Li, D. K., Khan, M. R., Wang, Z., Chongsrisawat, V., Swangsak, P., Teufel‐Schäfer, U., Engelmann, G., Goldschmidt, I., Baumann, U., Tokuhara, D., et al. (2020) · Liver International · doi:10.1111/liv.14658 · Cited by 43
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 45
Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD)
Han, M. A. T., Saouaf, R., Ayoub, W. S., Todo, T., Mena, E., & Noureddin, M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1299573 · Cited by 40
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease
Zhao, Y., & Li, H. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2041085 · Cited by 41
Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity
Runge, J. H., van Giessen, J., Draijer, L. G., Deurloo, E. E., Smets, A. M. J. B., Benninga, M. A., Koot, B. G. P., & Stoker, J. (2020) · European Radiology · doi:10.1007/s00330-020-07245-2 · Cited by 39
Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study
Weng, Z., Ou, W., Huang, J., Singh, M., Wang, M.-F., Zhu, Y., Kumar, R., & Lin, S. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s290465 · Cited by 39
Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease
Shao, C. X., Ye, J., Dong, Z., Li, F., Lin, Y., Liao, B., Feng, S., & Zhong, B. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211033119 · Cited by 39
Hepatocyte TGF‐β Signaling Inhibiting WAT Browning to Promote NAFLD and Obesity Is Associated With Let‐7b‐5p
Zhao, J., Hu, L., Gui, W., Xiao, L., Wang, W., Xia, J., Fan, H., Li, Z., Zhu, Q., Hou, X., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1892 · Cited by 39
Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease
Kim, G., Kim, K. J., Rhee, Y., & Lim, S.-K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182202 · Cited by 38
Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study
Gawrieh, S., Lake, J. E., Debroy, P., Sjoquist, J. A., Robison, M., Tann, M. A., Akisik, F. M., Bhamidipalli, S. S., Saha, C., Zachary, K. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000313 · Cited by 38
Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients
Sebastiani, G., Saeed, S., Lebouché, B., de Pokomandy, A., Szabo, J., Haraoui, L., Routy, J., Wong, P. Y. N., Deschênes, M., Ghali, P., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002412 · Cited by 38
Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis
Kuroda, H., Fujiwara, Y., Abe, T., Nagasawa, T., Oguri, T., Noguchi, S., Kamiyama, N., & Takikawa, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249493 · Cited by 38
The liver steatosis severity and lipid characteristics in primary biliary cholangitis
Zhang, Y., Hu, X., Chang, J. K., Chen, J., Han, X., Zhang, T., Shen, J., Shang, N., Han, J., Wang, H., et al. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01974-4 · Cited by 40
Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
Tseng, T., Lin, W., Ting, P., Huang, C., Chen, P., Gonzalez, G. V., & Lin, H. (2023) · Nutrients · doi:10.3390/nu15183997 · Cited by 40
The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention
Yang, T., Yin, J., Li, J., & Wang, Q. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.09.030 · Cited by 37
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population
Ciardullo, S., Monti, T., Grassi, G. M., Mancia, G., & Perseghin, G. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002835 · Cited by 37
Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens)
Ferraioli, G. (2021) · Journal of Medical Ultrasonics · doi:10.1007/s10396-021-01106-1 · Cited by 37
Self-citation
Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes
de Vries, M., Westerink, J., El-Morabit, F., Kaasjager, K. A. H., & de Valk, H. W. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109827 · Cited by 37
Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
Mandorfer, M., Scheiner, B., Stättermayer, A. F., Schwabl, P., Paternostro, R., Bauer, D. J. M., Schaefer, B., Zoller, H., Peck‐Radosavljevic, M., Trauner, M. A., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14856 · Cited by 37
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection
Liu, C., Cheng, P., Fang, Y., Chen, C.-Y., Kao, W., Lin, C., Yang, S., Shih, Y., Peng, C., Chang, Y., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.038 · Cited by 36
Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients
Rout, G., Kedia, S., Nayak, B., Yadav, R., Das, P., Acharya, S. K., Gunjan, D., Singh, V., Mahanta, M., Gupta, S., et al. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.02.010 · Cited by 36
Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease
Kamarajah, S. K., Chan, W., Mustapha, N. R. N., & Mahadeva, S. (2018) · Hepatology International · doi:10.1007/s12072-018-9843-4 · Cited by 36
Self-citation
Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method
Bende, F., Sporea, I., Șirli, R., Bâldea, V., Lazăr, A., Lupușoru, R., Fofiu, R., & Popescu, A. (2020) · Medical Ultrasonography · doi:10.11152/mu-2688 · Cited by 36
Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome
Shengir, M., Krishnamurthy, S., Ghali, P., Deschênes, M., Wong, P. Y. N., Chen, T., & Sebastiani, G. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i44.7046 · Cited by 37
Disease-Specific Imaging Utilizing Support Vector Machine Classification of H-Scan Parameters: Assessment of Steatosis in a Rat Model
Baek, J., Basavarajappa, L., Hoyt, K., & Parker, K. J. (2021) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2021.3137644 · Cited by 35
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
Zou, H., Ma, X., Pan, W. Q., & Xie, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1411802 · Cited by 41
Diagnostic value of serological biomarkers for detection of non‐alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV
Yanavich, C., Pacheco, A. G., Cardoso, S., Nunes, E., Chaves, U. S. B., de Freitas, G. R. P., dos Santos, R. R., Morata, M. M. S., Veloso, V. G., Grinsztejn, B. G. J., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13060 · Cited by 36
Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study
Fabrellas, N., Hernández, R., Graupera, I., Solà, E., Ramos, P. M., Martin, N., Sáez, G., Simón, C., Pérez, A., Graell, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200656 · Cited by 35

Authors: Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., Ferraioli, G., Chan, W.-K., Wong, V. W.-S., Myers, R. P., Chayama, K., Friedrich-Rust, M., Beaugrand, M., Shen, F., Hiriart, J.-B., Sarin, S. K., Badea, R., Jung, K. S., Marcellin, P., Filice, C., Mahadeva, S., Wong, G. L.-H., Crotty, P., Masaki, K., Bojunga, J., Bedossa, P., Keim, V., & Wiegand, J.
Affiliations: University Hospital Leipzig (DE)
IFB Adiposity Diseases (DE)
Echosens (France) (FR)
Shanghai Jiao Tong University (CN)
Institute of Liver and Biliary Sciences (IN)
Yonsei University (KR)
Inserm (FR)
University of Pavia (IT)
University of Malaya (MY)
Chinese University of Hong Kong (HK)
University of Calgary (CA)
Hiroshima University Hospital (JP)
Hôpital Jean-Verdier (FR)
Centre Hospitalier Universitaire de Bordeaux (FR)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
University Hospital Frankfurt (DE)
Corresponding author: Wiegand, Johannes
ORCID: Karlas, Thomas
Petroff, David
Sasso, Magali
Fan, Jian-Gao
Kumar, Manoj
Han, Kwang-Hyub
Cardoso, Ana C.
Ferraioli, Giovanna
Chan, Wah-Kheong
Wong, Vincent Wai-Sun
Chayama, Kazuaki
Shen, Feng
Hiriart, Jean-Baptiste
Sarin, Shiv K.
Badea, Radu
Marcellin, Patrick
Mahadeva, Sanjiv
Wong, Grace Lai-Hung
Crotty, Pam
Bojunga, Joerg
Wiegand, Johannes
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1022-1030
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2016.12.022
OpenAlex: W2564467149
Cited by: 1,275
References: 65
Citations by year: 2026: 164 · 2025: 185 · 2024: 180 · 2023: 139 · 2022: 161 · 2021: 150 · 2020: 117 · 2019: 77 · 2018: 67 · 2017: 31
FWCI: 7.94
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Ultrasound Imaging and Elastography
Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Ultrasound in Clinical Applications
Keywords: controlled attenuation parameter, hepatic steatosis, vibration-controlled transient elastography, FibroScan, chronic liver disease, diabetes mellitus, body mass index, liver ultrasound, receiver operating characteristic
MeSH terms: Adult, Fatty Liver, Female, Humans, Male, Middle Aged, ROC Curve, Ultrasonography, Meta-Analysis as Topic, Body Mass Index, Hepatocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks